Efficacy and tolerability of high dose

Table 1 Patient characteristics and tumor response to ethinylestradiol

Patient Number	Age at Rx (years)	Sites of disease	Previous endocrine therapies	Response at 6 months	Duration of Treatment (months)
1	85	Local	T, M, A, E, T	PR	7+
2	57	Local	T+G, M, Agt, Fr+G, T, A	PR	8
3	84	Bone, liver, mediastinal nodes	T, M, A, E	PR	12
4	76	Local	T, A, M	SD	36
5	80	Local, bone, pleura, ascites	T, F, A, M, E	PD	3
6	49	Bone	T+G, A+G, M, E+G	PD	6
7	79	Local, bone, lung	T, M, Agt, MPA, Fr	PD	2
8	74	Bone	M, E, T	PD	3
9	74	Bone	T, A, M, E	PD	2
10	84	Lung, pleura	A, M, E, F	PD	4
11	64	Bone	E, Lt, T	PD	6
12	64	Bone, liver	A, M	N/A*	0.5

Rx = Treatment; T = Tamoxifen; A = Anastrozole; E = Exemestane; M = Megestrol acetate; Lt = Letrozole; F = Fulvestrant; Agt = Aminoglutethimide; Fr = Formestane; MPA = Medroxyprogesterone acetate; G = Goserelin; N/A* = Not applicable as the patient was withdrawn due to side-effects.

ISSN: 1477-7819